首页 > 最新文献

Respirology Case Reports最新文献

英文 中文
Acute pulmonary thromboembolism with high-density emboli in the pulmonary artery detected on non-enhanced computed tomography. 非增强型计算机断层扫描发现肺动脉中有高密度栓子的急性肺血栓栓塞症。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1447
Shimpei Kajie, Kentaro Nakamura, Tomohiro Moriya, Tomoyuki Ogata, Takaaki Yamashita

The presence of high-density emboli in the pulmonary artery on non-enhanced computed tomography (CT) has high diagnostic performance for acute central pulmonary thromboembolism. Acute pulmonary thromboembolism is usually diagnosed by contrast-enhanced CT. However, it may be possible to achieve early diagnosis by identifying characteristic findings on non-enhanced CT.

非增强型计算机断层扫描(CT)显示肺动脉中有高密度栓子,对急性中枢性肺血栓栓塞症有很高的诊断率。急性肺血栓栓塞症通常通过造影剂增强 CT 诊断。不过,通过识别非增强 CT 上的特征性发现,也有可能实现早期诊断。
{"title":"Acute pulmonary thromboembolism with high-density emboli in the pulmonary artery detected on non-enhanced computed tomography.","authors":"Shimpei Kajie, Kentaro Nakamura, Tomohiro Moriya, Tomoyuki Ogata, Takaaki Yamashita","doi":"10.1002/rcr2.1447","DOIUrl":"10.1002/rcr2.1447","url":null,"abstract":"<p><p>The presence of high-density emboli in the pulmonary artery on non-enhanced computed tomography (CT) has high diagnostic performance for acute central pulmonary thromboembolism. Acute pulmonary thromboembolism is usually diagnosed by contrast-enhanced CT. However, it may be possible to achieve early diagnosis by identifying characteristic findings on non-enhanced CT.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01447"},"PeriodicalIF":0.8,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Pneumothorax And Symptom Evaluation (PASE) study: Bendopnoea in patients with pneumothorax. 气胸和症状评估(PASE)研究:气胸患者的憋气症状
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1443
Bianca M Iacopetta, Michaela Donaghy, Chloe Charlesworth, Carolyn J Peddle-McIntyre, Ai Ling Tan, Y C Gary Lee

Background: Pneumothorax can cause distressing breathlessness, however the effect of the accumulated air in the pleural space and its association with diaphragmatic function and symptoms of breathlessness is not well understood. Bendopnoea is an evolving clinical symptom that has been demonstrated as clinically useful in some heart and lung conditions. Whether bendopnoea is present in patients with pneumothorax, and its potential clinical usefulness has not yet been investigated. The PASE study is a pilot study to explore the incidence and clinical relevance of bendopnoea in patients with pneumothorax and may provide better understanding of pneumothorax related dyspnoea.

Methods: PASE is a prospective study. Eligible patients are assessed at baseline (pre air drainage/lung reinflation) and in patients whose pneumothorax resolves once the lung has re-expanded (post conservative management or air drainage procedure). Outcome measures include the incidence of bendopnoea, correlation of the associated symptoms (pain and breathlessness) to the severity of bendopnoea and the size of pneumothorax; and correlation with clinical outcome (i.e., response to air drainage/lung reinflation). The study will recruit 50 participants.

Discussion: This is the first study to explore bendopnoea in patients with pneumothorax. The presence and significance of bendopnoea in relation to clinical and physiological parameters in patients with pneumothorax requires investigation. The findings of this study may further current understanding of dyspnoea related pneumothorax.

Trial registration: Name of the registry: Australia New Zealand Clinical Trial Registry Trial registration number : ACTRN12623001109695p. URL of the trial registry record for this trial : https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386631&isReview=true Date of registration : Registered on 24 October 2023. Funding of the trial : This study has not received grant support. The study is sponsored by the Institute for Respiratory Health, a not-for-profit organisation. Name and contact information for the trial sponsor : Mr Bi Lam; Finance manager. Level 2, 6 Verdun Street, Nedlands, WA 6009. Role of sponsor : The funder is not involved in the planning of the study, gathering, analysing, and interpreting the data, or in preparing the manuscript. Protocol version : 1.

背景:气胸可导致呼吸困难,但胸膜腔内积聚空气的影响及其与横膈膜功能和呼吸困难症状的关系尚不十分清楚。憋气是一种不断发展的临床症状,已被证明对某些心肺疾病有临床作用。至于气胸患者是否会出现弯腰呼吸及其潜在的临床用途,目前尚未进行研究。PASE 研究是一项试验性研究,旨在探讨气胸患者弯腰呼吸困难的发生率和临床相关性,从而更好地了解与气胸相关的呼吸困难:PASE 是一项前瞻性研究。方法:PASE 是一项前瞻性研究,对符合条件的患者进行基线评估(空气引流前/肺重新充气),并在肺重新扩张后对气胸消退的患者进行评估(保守治疗或空气引流术后)。结果测量包括气胸发生率、相关症状(疼痛和呼吸困难)与气胸严重程度和气胸大小的相关性,以及与临床结果(即对空气引流/肺复张的反应)的相关性。该研究将招募 50 名参与者:讨论:这是第一项探讨气胸患者肺动脉弯曲的研究。需要对气胸患者气胸的存在及其与临床和生理参数的关系进行研究。这项研究的结果可能会进一步加深目前对与气胸相关的呼吸困难的理解:注册名称:澳大利亚新西兰临床试验登记处试验登记号:ACTRN12623001109695p。该试验登记记录的 URL : https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386631&isReview=true 登记日期 :注册日期 : 2023 年 10 月 24 日。试验资助:本研究未获得资助。本研究由非营利组织呼吸健康研究所赞助。试验发起人姓名和联系方式:Bi Lam 先生;财务经理。Level 2, 6 Verdun Street, Nedlands, WA 6009.赞助者的角色:赞助者不参与研究的计划、数据的收集、分析和解释,也不参与手稿的撰写。协议版本 : 1.
{"title":"The Pneumothorax And Symptom Evaluation (PASE) study: Bendopnoea in patients with pneumothorax.","authors":"Bianca M Iacopetta, Michaela Donaghy, Chloe Charlesworth, Carolyn J Peddle-McIntyre, Ai Ling Tan, Y C Gary Lee","doi":"10.1002/rcr2.1443","DOIUrl":"10.1002/rcr2.1443","url":null,"abstract":"<p><strong>Background: </strong>Pneumothorax can cause distressing breathlessness, however the effect of the accumulated air in the pleural space and its association with diaphragmatic function and symptoms of breathlessness is not well understood. Bendopnoea is an evolving clinical symptom that has been demonstrated as clinically useful in some heart and lung conditions. Whether bendopnoea is present in patients with pneumothorax, and its potential clinical usefulness has not yet been investigated. The PASE study is a pilot study to explore the incidence and clinical relevance of bendopnoea in patients with pneumothorax and may provide better understanding of pneumothorax related dyspnoea.</p><p><strong>Methods: </strong>PASE is a prospective study. Eligible patients are assessed at baseline (pre air drainage/lung reinflation) and in patients whose pneumothorax resolves once the lung has re-expanded (post conservative management or air drainage procedure). Outcome measures include the incidence of bendopnoea, correlation of the associated symptoms (pain and breathlessness) to the severity of bendopnoea and the size of pneumothorax; and correlation with clinical outcome (i.e., response to air drainage/lung reinflation). The study will recruit 50 participants.</p><p><strong>Discussion: </strong>This is the first study to explore bendopnoea in patients with pneumothorax. The presence and significance of bendopnoea in relation to clinical and physiological parameters in patients with pneumothorax requires investigation. The findings of this study may further current understanding of dyspnoea related pneumothorax.</p><p><strong>Trial registration: </strong><b><i>Name of the registry</i>:</b> Australia New Zealand Clinical Trial Registry <b><i>Trial registration number</i></b> : ACTRN12623001109695p. <b><i>URL of the trial registry record for this trial</i></b> : https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386631&isReview=true <b><i>Date of registration</i></b> : Registered on 24 October 2023. <b><i>Funding of the trial</i></b> : This study has not received grant support. The study is sponsored by the Institute for Respiratory Health, a not-for-profit organisation. <b><i>Name and contact information for the trial sponsor</i></b> : Mr Bi Lam; Finance manager. Level 2, 6 Verdun Street, Nedlands, WA 6009. <b><i>Role of sponsor</i></b> : The funder is not involved in the planning of the study, gathering, analysing, and interpreting the data, or in preparing the manuscript. <b><i>Protocol version</i></b> : 1.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01443"},"PeriodicalIF":0.8,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A double-blind randomized controlled trial of N-acetylcysteine (NAC) for the treatment of acute exacerbation of chronic obstructive pulmonary disease. N-乙酰半胱氨酸(NAC)治疗慢性阻塞性肺病急性加重的双盲随机对照试验。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1449
Wang Chung Kwok, Shung Kay Samuel Chan, Ka Yan Chiang, Chung Man James Ho

Background: Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with acute exacerbation (AECOPD) being a common sequalae which negatively impact health status, rates of hospitalization and readmission, and disease progression. N-acetylcysteine (NAC) has been studied in COPD in both stable state and acute exacerbations, which has been shown to have small beneficial effects in stable COPD, as well as AECOPD. Yet, there has been lack of study with well-designed protocol to assess the role of NAC in more objective outcomes in AECOPD.

Methods: This is a double-blind randomized controlled trial. Patients will be randomized in 1:1 ratio to receive oral NAC at 600 mg twice daily or placebo twice daily with standard of care. Partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) and the ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) will be measured on days 1 and 7. The following will be measure at baseline and on day 4 and 7: Forced expiratory volume in one second (FEV1), 24-hour sputum volume, oxygen saturation (SaO2), end-tidal CO2, Leicester Cough Questionnaire (LCQ) score, COPD Assessment Test (CAT) score, grading of wheeze and grade of dyspnoea; blood inflammatory markers (leucocyte count, neutrophil count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and high sensitivity CRP (hs-CRP)). Patients will be randomized to oral NAC at 600 mg twice daily or placebo for 7 days. The main outcome measures include: The difference in PaO2 on day 7. Secondary outcome: Change in following parameters on day 4/7 from baseline: FEV1, sputum volume, CAT score, LCQ score, SaO2, grade of wheeze; mMRC Dyspnoea Scale, end-tidal CO2, blood inflammatory marker, change in PaO2/FiO2 ratio from baseline to day 7, PaCO2 on day 7, 28 and 90 days' mortality, time to wean off supplemental oxygen, length of stay.Primary and secondary outcomes will be compared among the two treatment groups with two-sample t-test.

Discussion: We hypothesize that NAC use in COPD exacerbation can provide benefits in clinical and laboratory parameters.

Trial registration: Name of the registry : ClinicalTrials.gov Trial registration number : NCT05706402. URL of the trial registry record for this trial : https://classic.clinicaltrials.gov/ct2/show/NCT05706402 Date of registration : Registered on 11th January 2023 Funding of the trial : The Health and Medical Research Fund (HMRF). Name and contact information for the trial sponsor : Wang Chung Kwok, Clinical Assistant Professor, Honorary Associate Consultant, Queen Mary Hospital, The University of Hong Kong, Hong Kong. <

背景:慢性阻塞性肺疾病(COPD)是一种常见的呼吸系统疾病,急性加重(AECOPD)是一种常见的后遗症,对健康状况、住院率和再入院率以及疾病进展都有负面影响。N-乙酰半胱氨酸(NAC)已被用于慢性阻塞性肺病稳定期和急性加重期的研究,结果表明它对慢性阻塞性肺病稳定期和急性加重期均有微小的益处。然而,目前还缺乏设计良好的研究方案来评估 NAC 对 AECOPD 更客观结果的作用:这是一项双盲随机对照试验。患者将按 1:1 的比例随机接受口服 NAC,每次 600 毫克,每天两次;或接受安慰剂,每次 600 毫克,每天两次,同时接受标准护理。第 1 天和第 7 天将测量氧分压(PaO2)、二氧化碳分压(PaCO2)以及动脉血氧分压与吸入氧分压之比(PaO2/FiO2)。基线和第 4 天和第 7 天将测量以下项目:一秒钟用力呼气容积(FEV1)、24 小时痰量、血氧饱和度(SaO2)、潮气末二氧化碳、莱斯特咳嗽问卷(LCQ)评分、慢性阻塞性肺病评估测试(CAT)评分、喘息分级和呼吸困难分级;血液炎症指标(白细胞计数、中性粒细胞计数、红细胞沉降率(ESR)、C 反应蛋白(CRP)和高敏 CRP(hs-CRP))。患者将随机接受口服 NAC(600 毫克,每天两次)或安慰剂治疗,为期 7 天。主要结果指标包括第 7 天的 PaO2 差异。次要结果:第 4/7 天以下参数与基线相比的变化:mMRC呼吸困难量表、潮气末二氧化碳、血液炎症标志物、PaO2/FiO2比值从基线到第7天的变化、第7天的PaCO2、28天和90天的死亡率、脱离补充氧气的时间、住院时间:讨论:我们假设,在慢性阻塞性肺疾病加重期使用 NAC 可改善临床和实验室指标:登记名称:ClinicalTrials.gov 试验登记号:NCT05706402。该试验注册记录的网址: https://classic.clinicaltrials.gov/ct2/show/NCT05706402 注册日期 :注册日期 : 2023 年 1 月 11 日 试验资金来源 : 健康与医学研究基金 (HMRF)。试验发起人姓名和联系方式 : 王忠国,香港大学玛丽医院临床助理教授、名誉副顾问医生。贊助者的角色:贊助者沒有參與研究的策劃、數據的收集、分析和詮釋,亦沒有參與撰寫手稿。
{"title":"A double-blind randomized controlled trial of N-acetylcysteine (NAC) for the treatment of acute exacerbation of chronic obstructive pulmonary disease.","authors":"Wang Chung Kwok, Shung Kay Samuel Chan, Ka Yan Chiang, Chung Man James Ho","doi":"10.1002/rcr2.1449","DOIUrl":"10.1002/rcr2.1449","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with acute exacerbation (AECOPD) being a common sequalae which negatively impact health status, rates of hospitalization and readmission, and disease progression. N-acetylcysteine (NAC) has been studied in COPD in both stable state and acute exacerbations, which has been shown to have small beneficial effects in stable COPD, as well as AECOPD. Yet, there has been lack of study with well-designed protocol to assess the role of NAC in more objective outcomes in AECOPD.</p><p><strong>Methods: </strong>This is a double-blind randomized controlled trial. Patients will be randomized in 1:1 ratio to receive oral NAC at 600 mg twice daily or placebo twice daily with standard of care. Partial pressure of oxygen (PaO<sub>2</sub>), partial pressure of carbon dioxide (PaCO<sub>2</sub>) and the ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) will be measured on days 1 and 7. The following will be measure at baseline and on day 4 and 7: Forced expiratory volume in one second (FEV<sub>1</sub>), 24-hour sputum volume, oxygen saturation (SaO<sub>2</sub>), end-tidal CO<sub>2</sub>, Leicester Cough Questionnaire (LCQ) score, COPD Assessment Test (CAT) score, grading of wheeze and grade of dyspnoea; blood inflammatory markers (leucocyte count, neutrophil count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and high sensitivity CRP (hs-CRP)). Patients will be randomized to oral NAC at 600 mg twice daily or placebo for 7 days. The main outcome measures include: The difference in PaO<sub>2</sub> on day 7. Secondary outcome: Change in following parameters on day 4/7 from baseline: FEV<sub>1</sub>, sputum volume, CAT score, LCQ score, SaO<sub>2</sub>, grade of wheeze; mMRC Dyspnoea Scale, end-tidal CO<sub>2</sub>, blood inflammatory marker, change in PaO<sub>2</sub>/FiO<sub>2</sub> ratio from baseline to day 7, PaCO<sub>2</sub> on day 7, 28 and 90 days' mortality, time to wean off supplemental oxygen, length of stay.Primary and secondary outcomes will be compared among the two treatment groups with two-sample <i>t</i>-test.</p><p><strong>Discussion: </strong>We hypothesize that NAC use in COPD exacerbation can provide benefits in clinical and laboratory parameters.</p><p><strong>Trial registration: </strong><b><i>Name of the registry</i></b> : ClinicalTrials.gov <b><i>Trial registration number</i></b> : NCT05706402. <b><i>URL of the trial registry record for this trial</i></b> : https://classic.clinicaltrials.gov/ct2/show/NCT05706402 <b><i>Date of registration</i></b> : Registered on 11th January 2023 <b><i>Funding of the trial</i></b> : The Health and Medical Research Fund (HMRF). <b><i>Name and contact information for the trial sponsor</i></b> : Wang Chung Kwok, Clinical Assistant Professor, Honorary Associate Consultant, Queen Mary Hospital, The University of Hong Kong, Hong Kong. <b><","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01449"},"PeriodicalIF":0.8,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bronchoscopic retrieval of an aspirated tooth following high-speed motor vehicle accident. 高速车祸后用支气管镜取出吸入的牙齿。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-31 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1444
Hamza Azam, Peter Wu

A 28-year-old man aspirated a tooth into his right lower lobe bronchus following a high-speed motor vehicle accident. Initial retrieval attempts failed with a flexible bronchoscope, but a cryoprobe successfully dislodged and retrieved the tooth. Cryoprobe should be considered for bronchoscopic foreign body removal when conventional methods are unsuccessful.

一名 28 岁的男子在一次高速行驶的车祸中将一颗牙齿吸入右下叶支气管。最初尝试用软性支气管镜取出异物失败,但冷冻探针成功地将牙齿移位并取出。当传统方法不成功时,应考虑使用冷冻探针进行支气管镜异物取出。
{"title":"Bronchoscopic retrieval of an aspirated tooth following high-speed motor vehicle accident.","authors":"Hamza Azam, Peter Wu","doi":"10.1002/rcr2.1444","DOIUrl":"10.1002/rcr2.1444","url":null,"abstract":"<p><p>A 28-year-old man aspirated a tooth into his right lower lobe bronchus following a high-speed motor vehicle accident. Initial retrieval attempts failed with a flexible bronchoscope, but a cryoprobe successfully dislodged and retrieved the tooth. Cryoprobe should be considered for bronchoscopic foreign body removal when conventional methods are unsuccessful.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01444"},"PeriodicalIF":0.8,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Granular cell tumour-A case of recurrent pneumonia due to an endobronchial lesion. 颗粒细胞瘤--一例支气管内病变导致的复发性肺炎。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-31 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1436
Alwyn Mathew, Ahmad Al-Tanjy, Yazan Abdeen

Granular cell tumours are rare, mostly benign masses that arise from Schwann cells. Their pathophysiology is poorly understood, but the lesions are often seen in the breast, tongue, and skin. In this case report, we discuss a 34-year-old patient with recurrent pneumonia. The patient had several comorbidities, and was intubated due to respiratory distress and eventually placed on tracheostomy. During the procedure, she was noted to have a right middle lobe endobronchial lesion. It was excised and identified as a granular cell tumour. The patient was later weaned off the ventilator and discharged without any complications.

颗粒细胞瘤是一种罕见的良性肿瘤,多由许旺细胞引起。其病理生理学尚不十分清楚,但病变通常见于乳房、舌头和皮肤。在本病例报告中,我们讨论了一名患有反复肺炎的 34 岁患者。患者患有多种并发症,因呼吸困难而插管,最终被实施气管切开术。在手术过程中,她被发现右侧中叶支气管内病变。切除后确定为颗粒细胞瘤。患者后来脱离了呼吸机并出院,没有出现任何并发症。
{"title":"Granular cell tumour-A case of recurrent pneumonia due to an endobronchial lesion.","authors":"Alwyn Mathew, Ahmad Al-Tanjy, Yazan Abdeen","doi":"10.1002/rcr2.1436","DOIUrl":"10.1002/rcr2.1436","url":null,"abstract":"<p><p>Granular cell tumours are rare, mostly benign masses that arise from Schwann cells. Their pathophysiology is poorly understood, but the lesions are often seen in the breast, tongue, and skin. In this case report, we discuss a 34-year-old patient with recurrent pneumonia. The patient had several comorbidities, and was intubated due to respiratory distress and eventually placed on tracheostomy. During the procedure, she was noted to have a right middle lobe endobronchial lesion. It was excised and identified as a granular cell tumour. The patient was later weaned off the ventilator and discharged without any complications.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01436"},"PeriodicalIF":0.8,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of pleural and pericardium amyloidosis with effusion associated with multiple myeloma relapse. 一例与多发性骨髓瘤复发相关的胸膜和心包淀粉样变性伴有渗出的病例。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-31 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1445
Naoya Ishibashi, Takafumi Sugawara, Yugo Ashino, Ryuga Yabe, Ryo Nonomura, Yutaka Oshima, Takanobu Sasaki

An 80-year-old man with a history of Bence-Jones potein (BJP) λ-type multiple myeloma (MM), which had been in remission for 16 years, was examined for shortness of breath and was found to have bilateral pleural and pericardial effusions. A pleural fluid test and a pleural biopsy under local anaesthesia performed by a previous physician failed to make the diagnosis. Despite diuretic therapy, his condition necessitated frequent thoracentesis. The patient was referred to our hospital and thoracoscopic pleural and pericardial biopsies performed under general anaesthesia revealed λ-type AL amyloidosis, indicating a relapse of MM. Despite drug therapy for MM, the patient died from aspiration pneumonia. The case underscores the importance of considering amyloidosis in differential diagnoses for refractory effusions, especially in patients with a history of MM, even after long-term remission.

一名80岁的老人曾患本斯-琼斯波亭(Bence-Jones potein,BJP)λ型多发性骨髓瘤(MM),已缓解16年。之前的一名医生在局部麻醉下进行了胸腔积液检查和胸膜活检,但未能确诊。尽管接受了利尿剂治疗,但他的病情仍需要频繁进行胸腔穿刺。患者被转诊到我院,在全身麻醉下进行的胸腔镜胸膜和心包活检发现了λ型AL淀粉样变性,表明MM复发。尽管对 MM 进行了药物治疗,但患者还是死于吸入性肺炎。该病例强调了在难治性积液的鉴别诊断中考虑淀粉样变性的重要性,尤其是在有 MM 病史的患者中,即使长期缓解后也应考虑淀粉样变性。
{"title":"A case of pleural and pericardium amyloidosis with effusion associated with multiple myeloma relapse.","authors":"Naoya Ishibashi, Takafumi Sugawara, Yugo Ashino, Ryuga Yabe, Ryo Nonomura, Yutaka Oshima, Takanobu Sasaki","doi":"10.1002/rcr2.1445","DOIUrl":"10.1002/rcr2.1445","url":null,"abstract":"<p><p>An 80-year-old man with a history of Bence-Jones potein (BJP) λ-type multiple myeloma (MM), which had been in remission for 16 years, was examined for shortness of breath and was found to have bilateral pleural and pericardial effusions. A pleural fluid test and a pleural biopsy under local anaesthesia performed by a previous physician failed to make the diagnosis. Despite diuretic therapy, his condition necessitated frequent thoracentesis. The patient was referred to our hospital and thoracoscopic pleural and pericardial biopsies performed under general anaesthesia revealed λ-type AL amyloidosis, indicating a relapse of MM. Despite drug therapy for MM, the patient died from aspiration pneumonia. The case underscores the importance of considering amyloidosis in differential diagnoses for refractory effusions, especially in patients with a history of MM, even after long-term remission.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01445"},"PeriodicalIF":0.8,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pleuroparenchymal sarcoidosis: A rare manifestation mimicking metastatic lung cancer. 胸膜下肉样瘤病:模仿转移性肺癌的罕见表现。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-30 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1438
Eugene Gan, Chee Kiang Tay

A 66-year-old male from Myanmar presented with 3 months of cough and constitutional symptoms. He was an ex-tobacco user with no significant medical or exposure history. Chest x-ray showed ill-defined bilateral opacities and a left pleural effusion. Chest CT revealed two right lower lobe masses, and a moderate-sized left pleural effusion. PET-CT demonstrated hypermetabolic uptake in the thickened nodular pleura, pericardium, and hilar/mediastinal lymph nodes. EBUS-TBNA of the right lower paratracheal node and TBLB of the right lower lobe mass yielded epithelioid granulomas comprising multinucleated giant cells, epithelioid histiocytes and lymphoplasmacytic cells. Thoracoscopy revealed hard, whitish mass-like parietal pleural plaques, and pleural biopsy revealed identical histopathologic results. His symptoms resolved quickly after commencing prednisolone 25 mg daily. Chest CT at 6 months demonstrated near complete resolution of the parenchymal masses and pleural effusion. We highlight this unique case of pleuroparenchymal sarcoidosis mimicking metastatic lung cancer in a tuberculosis-endemic region.

一名来自缅甸的 66 岁男性因咳嗽和全身症状就诊 3 个月。他以前吸烟,没有明显的病史或接触史。胸部 X 光片显示双侧不明不白的肺不张和左侧胸腔积液。胸部 CT 显示两个右下叶肿块和一个中等大小的左胸腔积液。PET-CT 显示增厚的结节性胸膜、心包和腹腔/纵隔淋巴结有高代谢摄取。气管旁右下结节的 EBUS-TBNA 和右下叶肿块的 TBLB 发现了由多核巨细胞、上皮样组织细胞和淋巴浆细胞组成的上皮样肉芽肿。胸腔镜检查发现了坚硬的白色块状胸膜顶膜斑块,胸膜活检显示了相同的组织病理学结果。在开始使用每天 25 毫克的泼尼松龙后,他的症状很快得到缓解。6 个月后的胸部 CT 显示,实质肿块和胸腔积液几乎完全消退。我们重点介绍这例在结核病流行地区发生的模仿转移性肺癌的胸膜实质肉样瘤病。
{"title":"Pleuroparenchymal sarcoidosis: A rare manifestation mimicking metastatic lung cancer.","authors":"Eugene Gan, Chee Kiang Tay","doi":"10.1002/rcr2.1438","DOIUrl":"10.1002/rcr2.1438","url":null,"abstract":"<p><p>A 66-year-old male from Myanmar presented with 3 months of cough and constitutional symptoms. He was an ex-tobacco user with no significant medical or exposure history. Chest x-ray showed ill-defined bilateral opacities and a left pleural effusion. Chest CT revealed two right lower lobe masses, and a moderate-sized left pleural effusion. PET-CT demonstrated hypermetabolic uptake in the thickened nodular pleura, pericardium, and hilar/mediastinal lymph nodes. EBUS-TBNA of the right lower paratracheal node and TBLB of the right lower lobe mass yielded epithelioid granulomas comprising multinucleated giant cells, epithelioid histiocytes and lymphoplasmacytic cells. Thoracoscopy revealed hard, whitish mass-like parietal pleural plaques, and pleural biopsy revealed identical histopathologic results. His symptoms resolved quickly after commencing prednisolone 25 mg daily. Chest CT at 6 months demonstrated near complete resolution of the parenchymal masses and pleural effusion. We highlight this unique case of pleuroparenchymal sarcoidosis mimicking metastatic lung cancer in a tuberculosis-endemic region.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01438"},"PeriodicalIF":0.8,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective bronchial occlusion for acquired bronchobiliary fistula caused by treatment of hepatocellular carcinoma: A case series. 选择性支气管闭塞术治疗肝癌引起的后天性支气管胆道瘘:病例系列。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-30 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1440
Bi Zhao, Rui Chen Huang, Yang Xia, Yuchao Dong, Haidong Huang, Lijun Zhao, Wei Zhang

Acquired bronchobiliary fistula (ABBF) is very rare among the complications that occur in patients with hepatocellular carcinoma (HCC) after treatment. Although surgery and drainage have been the main methods for treating ABBF for a long time, they are not entirely suitable for patients with refractory ABBF resulting from HCC therapy. In this study, we present four cases of ABBF caused by HCC treatment, who were treated using selective bronchial occlusion (SBO). Among the 4 patients with ABBF treated with SBO, 3 cases successfully blocked ABBF with SBO, and the treatment success rate was 75%. All successfully treated patients reported disappearance of symptoms of bilioptysis and cough was alleviated. No life-threatening adverse reactions were reported following SBO intervention, and no deaths occurred. We believe that the use of video bronchoscopy to place a self-made silicone plug in the bronchus to treat refractory ABBF is a feasible palliative treatment, which can significantly improve the condition of ABBF patients.

获得性支气管胆管瘘(ABBF)是肝细胞癌(HCC)患者治疗后出现的并发症中非常罕见的一种。虽然长期以来手术和引流一直是治疗 ABBF 的主要方法,但它们并不完全适用于 HCC 治疗导致的难治性 ABBF 患者。在本研究中,我们介绍了四例因 HCC 治疗导致的 ABBF 患者,他们均接受了选择性支气管闭塞(SBO)治疗。在采用 SBO 治疗的 4 例 ABBF 患者中,3 例成功阻断了 ABBF,治疗成功率为 75%。所有成功治疗的患者均表示胆汁栓塞症状消失,咳嗽减轻。SBO 介入治疗后未出现危及生命的不良反应,也没有死亡病例。我们认为,使用视频支气管镜将自制的硅胶塞置入支气管治疗难治性 ABBF 是一种可行的姑息治疗方法,可显著改善 ABBF 患者的病情。
{"title":"Selective bronchial occlusion for acquired bronchobiliary fistula caused by treatment of hepatocellular carcinoma: A case series.","authors":"Bi Zhao, Rui Chen Huang, Yang Xia, Yuchao Dong, Haidong Huang, Lijun Zhao, Wei Zhang","doi":"10.1002/rcr2.1440","DOIUrl":"10.1002/rcr2.1440","url":null,"abstract":"<p><p>Acquired bronchobiliary fistula (ABBF) is very rare among the complications that occur in patients with hepatocellular carcinoma (HCC) after treatment. Although surgery and drainage have been the main methods for treating ABBF for a long time, they are not entirely suitable for patients with refractory ABBF resulting from HCC therapy. In this study, we present four cases of ABBF caused by HCC treatment, who were treated using selective bronchial occlusion (SBO). Among the 4 patients with ABBF treated with SBO, 3 cases successfully blocked ABBF with SBO, and the treatment success rate was 75%. All successfully treated patients reported disappearance of symptoms of bilioptysis and cough was alleviated. No life-threatening adverse reactions were reported following SBO intervention, and no deaths occurred. We believe that the use of video bronchoscopy to place a self-made silicone plug in the bronchus to treat refractory ABBF is a feasible palliative treatment, which can significantly improve the condition of ABBF patients.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01440"},"PeriodicalIF":0.8,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IgG4-related pleural disease diagnosed by thoracoscopic pleural biopsy: A case report. 通过胸腔镜胸膜活检确诊的 IgG4 相关胸膜疾病:病例报告。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-30 eCollection Date: 2024-08-01 DOI: 10.1002/rcr2.1442
Azusa Miyoshi, Hideki Katsura, Tomohiro Akaba, Mitsuko Kondo, Etsuko Tagaya

Here we report a rare case of immunoglobulin G4 (IgG4)-related pleural disease diagnosed using a thoracoscopic pleural biopsy. A 66-year-old man was admitted to our hospital with right-dominant bilateral pleural effusions and gradually worsening dyspnoea. Chest radiographs revealed right-dominant pleural effusions, while chest computed tomography showed bilateral pleural effusions without parenchymal lesions. Although the bilateral pleural effusions were exudative with an increased number of lymphocytes, the definitive diagnosis was initially elusive. High IgG4 levels in the serum and pleural effusions were observed. A pathological evaluation of a right pleural biopsy specimen collected via video-assisted thoracoscopic surgery showed fibrosis-associated lymphoplasmacytic infiltration, 45-60 IgG4-positive plasma cells per high-power field, and an IgG4/immunoglobulin G ratio of 40%. Consequently, the patient was diagnosed with IgG4-related pleural disease. The bilateral pleural effusions improved after corticosteroid therapy.

我们在此报告一例罕见的免疫球蛋白 G4(IgG4)相关胸膜疾病病例,该病例是通过胸腔镜胸膜活检确诊的。一名 66 岁的男性因右侧双侧胸腔积液和逐渐加重的呼吸困难入住我院。胸片显示右侧胸腔积液,胸部计算机断层扫描显示双侧胸腔积液,但无实质病变。虽然双侧胸腔积液呈渗出性,且淋巴细胞数量增多,但起初无法明确诊断。血清和胸腔积液中的 IgG4 水平很高。通过视频辅助胸腔镜手术采集的右侧胸膜活检标本的病理评估显示,纤维化相关淋巴浆细胞浸润,每个高倍视野有 45-60 个 IgG4 阳性浆细胞,IgG4/免疫球蛋白 G 的比率为 40%。因此,患者被诊断为 IgG4 相关性胸膜疾病。经过皮质类固醇治疗后,双侧胸腔积液有所好转。
{"title":"IgG4-related pleural disease diagnosed by thoracoscopic pleural biopsy: A case report.","authors":"Azusa Miyoshi, Hideki Katsura, Tomohiro Akaba, Mitsuko Kondo, Etsuko Tagaya","doi":"10.1002/rcr2.1442","DOIUrl":"10.1002/rcr2.1442","url":null,"abstract":"<p><p>Here we report a rare case of immunoglobulin G4 (IgG4)-related pleural disease diagnosed using a thoracoscopic pleural biopsy. A 66-year-old man was admitted to our hospital with right-dominant bilateral pleural effusions and gradually worsening dyspnoea. Chest radiographs revealed right-dominant pleural effusions, while chest computed tomography showed bilateral pleural effusions without parenchymal lesions. Although the bilateral pleural effusions were exudative with an increased number of lymphocytes, the definitive diagnosis was initially elusive. High IgG4 levels in the serum and pleural effusions were observed. A pathological evaluation of a right pleural biopsy specimen collected via video-assisted thoracoscopic surgery showed fibrosis-associated lymphoplasmacytic infiltration, 45-60 IgG4-positive plasma cells per high-power field, and an IgG4/immunoglobulin G ratio of 40%. Consequently, the patient was diagnosed with IgG4-related pleural disease. The bilateral pleural effusions improved after corticosteroid therapy.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 8","pages":"e01442"},"PeriodicalIF":0.8,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case of allergic bronchopulmonary mycosis complicating pulmonary pleomorphic carcinoma. 肺胸膜癌并发过敏性支气管肺霉菌病的罕见病例。
IF 0.8 Q4 RESPIRATORY SYSTEM Pub Date : 2024-07-23 eCollection Date: 2024-07-01 DOI: 10.1002/rcr2.1439
Yoshihiro Okada, Kazuhiro Sakaguchi, Kazuya Tanimura, Kazuhide Horimoto, Takeshi Kawaguchi, Masatsugu Hamaji, Maiko Takeda, Shigeto Hontsu, Shigeo Muro

A 72-year-old man with productive cough and wheezing was referred to our institution for a growing mass shadow and central bronchiectasis in the right lower lobe on computed tomography. Based on the symptoms, elevated Aspergillus-specific immunoglobulin E levels, and radiological findings, allergic bronchopulmonary mycosis (ABPM) was suspected according to the Japanese clinical diagnostic criteria. The patient refused bronchoscopic examination, and oral prednisolone (0.5 mg/kg/day) improved the symptoms; however, the mass shadow continued to grow. Subsequently, bronchoscopy revealed mucus plugs and an endobronchial tumour with a whitish surface. The tumour was surgically resected, and the pathological diagnosis was a coexistence of ABPM and pulmonary pleomorphic carcinoma. To the best of our knowledge, this is the first case of ABPM developing at the site of pulmonary pleomorphic carcinoma. Careful bronchoscopic examinations and histopathological evaluations of the surgical specimen led to a prompt and accurate diagnosis.

一名 72 岁的男性因咳嗽、气喘,右下叶肿块影不断增大并伴有中央支气管扩张,经计算机断层扫描转诊至我院。根据症状、曲霉菌特异性免疫球蛋白 E 水平升高和放射学检查结果,按照日本临床诊断标准,怀疑为过敏性支气管肺霉菌病(ABPM)。患者拒绝支气管镜检查,口服泼尼松龙(0.5 毫克/千克/天)后症状有所改善,但肿块阴影仍在继续扩大。随后,支气管镜检查发现了粘液栓和表面发白的支气管内肿瘤。肿瘤被手术切除,病理诊断为 ABPM 和肺胸膜癌并存。据我们所知,这是首例在肺胸膜癌部位发生 ABPM 的病例。对手术标本进行仔细的支气管镜检查和组织病理学评估后,我们迅速做出了准确诊断。
{"title":"A rare case of allergic bronchopulmonary mycosis complicating pulmonary pleomorphic carcinoma.","authors":"Yoshihiro Okada, Kazuhiro Sakaguchi, Kazuya Tanimura, Kazuhide Horimoto, Takeshi Kawaguchi, Masatsugu Hamaji, Maiko Takeda, Shigeto Hontsu, Shigeo Muro","doi":"10.1002/rcr2.1439","DOIUrl":"10.1002/rcr2.1439","url":null,"abstract":"<p><p>A 72-year-old man with productive cough and wheezing was referred to our institution for a growing mass shadow and central bronchiectasis in the right lower lobe on computed tomography. Based on the symptoms, elevated Aspergillus-specific immunoglobulin E levels, and radiological findings, allergic bronchopulmonary mycosis (ABPM) was suspected according to the Japanese clinical diagnostic criteria. The patient refused bronchoscopic examination, and oral prednisolone (0.5 mg/kg/day) improved the symptoms; however, the mass shadow continued to grow. Subsequently, bronchoscopy revealed mucus plugs and an endobronchial tumour with a whitish surface. The tumour was surgically resected, and the pathological diagnosis was a coexistence of ABPM and pulmonary pleomorphic carcinoma. To the best of our knowledge, this is the first case of ABPM developing at the site of pulmonary pleomorphic carcinoma. Careful bronchoscopic examinations and histopathological evaluations of the surgical specimen led to a prompt and accurate diagnosis.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 7","pages":"e01439"},"PeriodicalIF":0.8,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Respirology Case Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1